By: IPP Bureau
Last updated : September 14, 2023 4:05 pm
The inspection was a cGMP Inspection and had ended with NIL observations
Zydus has received the EIR report from the USFDA for the inspection conducted at the injectables manufacturing facility at Zydus Biotech Park located at Changodar, Ahmedabad from 5th to 13th June, 2023. The inspection was a cGMP Inspection and had ended with NIL observations.
The Zydus Group with an overarching purpose of empowering people with freedom to live healthier and more fulfilled lives, is an innovative, global life sciences company that discovers, develops, manufactures, and markets a broad range of healthcare therapies.
The group employs nearly 24,000 people worldwide and is driven by its mission to unlock new possibilities in life sciences through quality healthcare solutions that impact lives. The group aspires to transform lives through path-breaking discoveries.